Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ETF (BBH), a passively managed exchange traded fund launched on December 20, ...

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...

There is no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines and treatment options. Moreover, increasing mergers and ...

A run-up in biotech and drug stocks that sent valuations soaring through the second half of 2025 was looking a bit shaky on ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

This rally in Illumina proved a shot in the arm for one of the most Illumina-sensitive funds, the ARK Genomic Revolution ETF (BATS:ARKG). It surged about 4% this week to outperform broader biotech ...

After a strong biotech rebound, one fund quietly walked away from sector beta, and the timing says more than the trade itself.

Investors and vaccine makers like Moderna MRNA and Johnson & Johnson JNJ have reasons to cheer the latest update concerning the application of COVID-19 booster shots. In an effort to combat the ...